Professor Paul Riley will lead the scientific vision of the first institute of its kind in the world to physically merge the disciplines of developmental biology and regenerative medicine in a common goal to treat some of the world\u2019s most prolific diseases.
The awardees for the second round of the University of Oxford\u2019s Enriching Engagement funding scheme have now been announced, including a project from Paediatrics.
In an opinion piece for The Guardian, Professor Matthew Snape discusses the initial results of his team's antibody study in the context of coronavirus risk to school children.
Oligonucleotides - short DNA or RNA molecules - have great therapeutic application for a range of diseases. Yet, their potential has not been fully unleashed because of challenges linked to efficient delivery. Read more to find out about recent developments in oligonucleotide modifications, and the platforms that may be used to deliver them to target sites.
Congratulations to Professor Andrew Pollard who is the Winner of the Policy Engagement category in the Vice-Chancellor Innovation Awards 2020 for his work on Global policy on typhoid vaccines through research at Oxford!
A team of scientists at Oxford Vaccine Group (Department of Paediatrics) and Oxford University\u2019s Jenner Institute has taken the next step towards the discovery of a safe, effective and accessible vaccine against coronavirus.
The European Commission has granted Marketing Authorisation to Janssen for a new Ebola vaccine, developed in partnership with the University of Oxford.
The Duke of Cambridge visits the University of Oxford\u2019s Oxford Vaccine Centre, to learn more about their work to establish a viable vaccine against COVID-19.
AstraZeneca has reached an agreement with Europe\u2019s Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 million doses of the University of Oxford\u2019s COVID-19 vaccine, with deliveries starting by the end of 2020.
Bristol Science Film Festival awarded the Professional Science Fact Film Prize to \"The Adventures of Alice in Typhoidland\" co-created by the Oxford Vaccine Group.
The Academy of Medical Sciences, the independent body in the UK representing the diversity of medical science, has announced the election of fifty new Fellows, including Professor Matthew Wood from the Department of Paediatrics.
How can researching a cohort of infants from KwaZulu-Natal in South Africa help explain differing HIV susceptibility of males and females? Professor Philip Goulder, head of the HIV Research Group, discusses the Baby Cure study.
The University of Oxford has today announced an agreement with the UK-based global biopharmaceutical company AstraZeneca for the further development, large-scale manufacture and potential distribution of the COVID-19 vaccine candidate currently being trialled by the Oxford Vaccine Group.
University of Oxford researchers have begun testing a COVID-19 vaccine in human volunteers in Oxford today. Around 1,110 people will take part in the trial, half receiving the vaccine and the other half (the control group) receiving a widely available meningitis vaccine.
A multi-site project, called \u2018What\u2019s the STORY?\u2019 has received funding from UK Research and Innovation (UKRI) to assess novel coronavirus infection rates in children and teenagers across the UK. Given the importance of this study to the national Covid-19 response it has been deemed a priority study for the National Institute for Health Research\u2019s (NIHR) Urgent Public Health Response.
Five projects from across Oxford University's Medical Sciences Division, including a project led by Professor Matthew Snape from the Oxford Vaccine Group, are among twenty-one new studies into the novel coronavirus which have been funded by the UK government.
![\"A](\"https://www.paediatrics.ox.ac.uk/news/paul-riley-appointed-director-of-oxford2019s-institute-of-developmental-and-regenerative-medicine/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n